Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Dupilumab Efficacy in Patients with a Type 2 Phenotype with or without Allergic Asthma

admin by admin
January 10, 2023
in News


The following is the summary of  “Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype”  published in the November 2022 issue of Allergy and Clinical Immunology: In Practice by Rabe, et al.


Patients with type 2 inflammation (blood eosinophils ≥150 cells/μL, fractional exhaled nitric oxide [FENO] ≥20 parts per billion, or allergic asthma) whose asthma is not controlled by high-dose inhaled corticosteroids should be evaluated for add-on biologics, according to the Global Initiative for Asthma report. Patients with uncontrolled moderate to severe asthma, defined as eosinophils more than or equal to 150 cells/μL and/or Feno greater than or equal to 25 parts per billion, responded well to add-on dupilumab versus placebo in the QUEST (NCT02414854) trial. Evaluate the efficacy of dupilumab in individuals with a type 2 phenotype, either with or without an allergic asthma phenotype.

Dupilumab 200/300 mg was added to matched placebo every 2 weeks for 52 weeks for patients aged 12 and up. Baseline serum total IgE greater than or equal to 30 IU/mL and 1 or more perennial aeroallergen-specific IgE levels greater than or equal to 0.35 kU/L were used to define the allergic asthma phenotype. Patients with an allergic phenotype and a baseline blood eosinophil count greater than or equal to 150 cells/μL and/or Feno greater than or equal to 20 ppb were compared to patients with a nonallergic phenotype in terms of the annualized rate of severe asthma exacerbations and changes in pre- and post-bronchodilator FEV1.  Among the QUEST cohort of 1,902 patients, 83.3% had eosinophils and/or Feno levels above Global Initiative for Asthma standards, and 56.9% showed evidence of allergic asthma. 

Significant improvements in pre- and post-bronchodilator forced expiratory volume in 1 (FEV1) were seen in individuals with increased type 2 biomarkers, regardless of whether or not they showed indications of an allergic asthma phenotype, after treatment with dupilumab (48.8% reduction, 64.0% reduction). Dupilumab was shown to dramatically reduce exacerbations and improve lung function in people with type 2 biomarkers above Global Initiative for Asthma standards. The presence of allergies has no bearing on how effective the treatment was.

Source: sciencedirect.com/science/article/pii/S2213219822006511



Source link

Advertisement Banner
Previous Post

New DAISY Ethics Award Celebrates Nurses’ Integrity

Next Post

AAP guidance on treating obesity in kids recommends drugs, surgery

Related Posts

News

Treatment of Older Adults’ Constipation Caused by Opioids

February 7, 2023
News

Serious Illness: Advance Care Planning

February 6, 2023
News

Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality

February 5, 2023
News

#VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension

February 4, 2023
News

Risk of Severe COVID-19 Infection and Other SARIs in Preexisting Neuropsychiatric Conditions

February 3, 2023
News

Vitiligo Responding and Refractory Alopecia Areata During the Monotherapy With Tofacitinib

February 2, 2023
Next Post

AAP guidance on treating obesity in kids recommends drugs, surgery

Recommended

The Consequences Patient Care Providers Face When They Fail to Use Their Tools

1 month ago

THCB Gang Episode 108, Thursday December 1 – The Health Care Blog

2 months ago

Our Top 5 Airway Management Blogs of 2022

1 month ago

Hospital systems create in-house staffing teams to fuel shortages

1 month ago

Concerns emerging for obesity care startups that offer medications

3 months ago

© 2022 Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.